{"title":"Creating an AI-first drug discovery engine","authors":"","doi":"10.1038/d41573-024-00149-6","DOIUrl":null,"url":null,"abstract":"Najat Khan — Chief R&D Officer and Chief Commercial Officer at Recursion — discusses the proposed merger of Recursion and Exscientia.","PeriodicalId":18847,"journal":{"name":"Nature Reviews Drug Discovery","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/d41573-024-00149-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Najat Khan — Chief R&D Officer and Chief Commercial Officer at Recursion — discusses the proposed merger of Recursion and Exscientia.